Hamilton Locke advised listed France-based molecular diagnostic group Novacyt, through its wholly owned UK subsidiary Novacyt UK Holdings Limited, on its announced acquisition of Southern Cross Diagnostics Pty Ltd, a leading Sydney-based distributor specialising in diagnostic and life sciences products.
Hamilton Locke worked alongside the corporate teams at Addleshaw Goddard LLP and Frieh Brault & Associes advising Novacyt on all Australian aspects, including FIRB, ACCC, legal and employment due diligence and transaction assistance, on its acquisition of Southern Cross Diagnostics Pty Ltd.
This transaction strengthens Novacyt’s positioning in the distribution of diagnostic and life sciences products in Australia, expanding the group’s product portfolio and geographical expansion.
Commenting on the transaction, James Delesclefs said: “We are proud to have supported Novacyt Group with this strategic acquisition that will expand its product offering and capabilities in Australia, and to have worked alongside longstanding partner Addleshaw Goddard UK and the team at Frieh Brault & Associes in France on another complex cross-border transaction.”
The M&A team was led by Partner James Delesclefs and Consultant Gonzalo Castro and Roger Hart and Lucie Walker at Addleshaw Goddard.
